Exelixis (LTS:0IJO) Current Accrued Expense : $94 Mil (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Exelixis Current Accrued Expense?

Exelixis's Current Accrued Expense for the quarter that ended in Mar. 2024 was $94 Mil.

Exelixis's quarterly Current Accrued Expense increased from Sep. 2023 ($90 Mil) to Dec. 2023 ($99 Mil) but then declined from Dec. 2023 ($99 Mil) to Mar. 2024 ($94 Mil).

Exelixis's annual Current Accrued Expense declined from Dec. 2021 ($164 Mil) to Dec. 2022 ($85 Mil) but then increased from Dec. 2022 ($85 Mil) to Dec. 2023 ($99 Mil).

Exelixis Current Accrued Expense Historical Data

The historical data trend for Exelixis's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Exelixis Current Accrued Expense Chart

Exelixis Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Current Accrued Expense

Get a 7-Day Free Trial

50.63

64.71

164.30

85.26

99.15

Exelixis Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Current Accrued Expense	Get a 7-Day Free Trial															82.53	82.22	90.11	99.15	94.04

Exelixis Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

Exelixis Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of Exelixis's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Exelixis (LTS:0IJO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Exelixis Inc (LTS:0IJO) » Definitions » Current Accrued Expense

Comparable Companies

Traded in Other Exchanges

EXEL:USA EX9:Germany

Address

1851 Harbor Bay Parkway, Alameda, CA, USA, 94502

Website

https://www.exelixis.com

Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.

Exelixis (LTS:0IJO) Headlines

No Headlines